Suppr超能文献

针对胸苷激酶 1 的人源单域抗体 (sdAb) 的筛选及其纳入 sdAb-Fc 抗体构建体中,以潜在用于癌症治疗。

Selection of human single domain antibodies (sdAb) against thymidine kinase 1 and their incorporation into sdAb-Fc antibody constructs for potential use in cancer therapy.

机构信息

Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT, United States of America.

出版信息

PLoS One. 2022 Mar 3;17(3):e0264822. doi: 10.1371/journal.pone.0264822. eCollection 2022.

Abstract

Thymidine Kinase 1 (TK1) is primarily known as a cancer biomarker with good prognostic capabilities for both hematological and solid malignancies. However, recent studies targeting TK1 at protein and mRNA levels have shown that TK1 may be useful as a therapeutic target. In order to examine the use of TK1 as a therapeutic target, it is necessary to develop therapeutics specific for it. Single domain antibodies (sdAbs), represent an exciting approach for the development of immunotherapeutics due to their cost-effective production and higher tumor penetration than conventional antibodies. In this study, we isolated sdAb fragments specific to human TK1 from a human sdAb library. A total of 400 sdAbs were screened through 5 rounds of selection by monoclonal phage ELISA. The most sensitive sdAb fragments were selected as candidates for preclinical testing. The sdAb fragments showed specificity for human TK1 in phage ELISA, Western blot analysis and had an estimated limit of detection of 3.9 ng/ml for the antibody fragments 4-H-TK1_A1 and 4-H-TK1_D1. The antibody fragments were successfully expressed and used for detection of membrane associated TK1 (mTK1) through flow cytometry on cancer cells [lung (95%), colon (87%), breast (~53%)] and healthy human mononuclear cells (MNC). The most sensitive antibody fragments, 4-H-TK1_A1 and 4-H-TK1_D1 were fused to an engineered IgG1 Fc fragment. When added to cancer cells expressing mTK1 co-cultured with human MNCs, the anti-TK1-sdAb-IgG1_A1 and D1 were able to elicit a significant antibody-dependent cell-mediated cytotoxicity (ADCC) response against lung cancer cells compared to isotype controls (P<0.0267 and P<0.0265, respectively). To our knowledge this is the first time that the isolation and evaluation of human anti-TK1 single domain antibodies using phage display technology has been reported. The antibody fragments isolated here may represent a valuable resource for the detection and the targeting of TK1 on tumor cells.

摘要

胸苷激酶 1(TK1)主要作为癌症生物标志物,对血液系统和实体恶性肿瘤均具有良好的预后能力。然而,最近针对 TK1 蛋白和 mRNA 水平的研究表明,TK1 可能作为一种治疗靶点具有一定的应用价值。为了研究 TK1 作为治疗靶点的可能性,有必要开发针对它的治疗方法。单域抗体(sdAb)因其生产成本低、比传统抗体具有更高的肿瘤穿透性,成为免疫治疗开发的一种很有前途的方法。在本研究中,我们从人源 sdAb 文库中分离出了针对人 TK1 的 sdAb 片段。通过单克隆噬菌体 ELISA 进行了 5 轮筛选,共筛选了 400 个 sdAb。选择最敏感的 sdAb 片段作为临床前检测的候选物。噬菌体 ELISA、Western blot 分析结果显示 sdAb 片段与人 TK1 具有特异性,并且抗体片段 4-H-TK1_A1 和 4-H-TK1_D1 的检测限估计为 3.9ng/ml。sdAb 片段成功表达,并通过流式细胞术用于检测癌细胞[肺癌(95%)、结肠癌(87%)、乳腺癌(~53%)]和健康人单核细胞(MNC)上的膜结合 TK1(mTK1)。最敏感的抗体片段 4-H-TK1_A1 和 4-H-TK1_D1 与工程化 IgG1 Fc 片段融合。当与表达 mTK1 的癌细胞共培养并加入与人类 MNC 一起培养时,与同型对照相比,抗-TK1-sdAb-IgG1_A1 和 D1 能够引发针对肺癌细胞的显著抗体依赖的细胞介导的细胞毒性(ADCC)反应(分别为 P<0.0267 和 P<0.0265)。据我们所知,这是首次使用噬菌体展示技术分离和评估人源抗 TK1 单域抗体。本文分离的抗体片段可能为肿瘤细胞上 TK1 的检测和靶向提供有价值的资源。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/714e/8893706/629425bf9894/pone.0264822.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验